Literature DB >> 25878031

Myocardial Infarction Superimposed on Aging: MMP-9 Deletion Promotes M2 Macrophage Polarization.

Andriy Yabluchanskiy1, Yonggang Ma1, Kristine Y DeLeon-Pennell1, Raffaele Altara1, Ganesh V Halade1, Andrew P Voorhees2, Nguyen T Nguyen3, Yu-Fang Jin3, Michael D Winniford4, Michael E Hall4, Hai-Chao Han2, Merry L Lindsey5.   

Abstract

In this study, we examined the combined effect of aging and myocardial infarction on left ventricular remodeling, focusing on matrix metalloproteinase (MMP)-9-dependent mechanisms. We enrolled 55 C57BL/6J wild type (WT) and 85 MMP-9 Null (Null) mice of both sexes at 11-36 months of age and evaluated their response at Day 7 post-myocardial infarction. Plasma MMP-9 levels positively linked to age in WT mice (r = .46, p = .001). MMP-9 deletion improved survival (76% for WT vs 88% for Null, p = .021). Post-myocardial infarction, there was a progressive increase in left ventricular dilation with age in WT but not in Null mice. By inflammatory gene array analysis, WT mice showed linear age-dependent increases in three different proinflammatory genes (C3, CCl4, and CX3CL1; all p < .05), whereas Null mice showed increases in three proinflammatory genes (CCL5, CCL9, and CXCL4; all p < .05) and seven anti-inflammatory genes (CCL1, CCL6, CCR1, IL11, IL1r2, IL8rb, and Mif; all p < .05). Compared with WT, macrophages isolated from Null left ventricle infarct demonstrated enhanced expression of anti-inflammatory M2 markers CD163, MRC1, TGF-β1, and YM1 (all p < .05), without affecting proinflammatory M1 markers. In conclusion, MMP-9 deletion stimulated anti-inflammatory polarization of macrophages to attenuate left ventricle dysfunction in the aging post-myocardial infarction.
© The Author 2015. Published by Oxford University Press on behalf of the Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Aging; Cardiac remodeling; M2 phenotype.; Macrophage polarization

Mesh:

Substances:

Year:  2015        PMID: 25878031      PMCID: PMC5175450          DOI: 10.1093/gerona/glv034

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  40 in total

1.  Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Ying Ann Chiao; Elizabeth F Lopez; Andrew P Voorhees; Hiroe Toba; Michael E Hall; Hai-Chao Han; Merry L Lindsey; Yu-Fang Jin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-21       Impact factor: 4.733

2.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.

Authors:  D BenEzra
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-11       Impact factor: 4.799

3.  Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.

Authors:  Damian J Kelly; Tony Gershlick; Bernhard Witzenbichler; Giulio Guagliumi; Martin Fahy; George Dangas; Roxana Mehran; Gregg W Stone
Journal:  Am Heart J       Date:  2011-10       Impact factor: 4.749

4.  Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit.

Authors:  A M Romanic; C L Burns-Kurtis; B Gout; I Berrebi-Bertrand; E H Ohlstein
Journal:  Life Sci       Date:  2001-01-05       Impact factor: 5.037

5.  Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells.

Authors:  Z Han; J Ni; P Smits; C B Underhill; B Xie; Y Chen; N Liu; P Tylzanowski; D Parmelee; P Feng; I Ding; F Gao; R Gentz; D Huylebroeck; J Merregaert; L Zhang
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

6.  Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction.

Authors:  Marcin Bujak; Hyuk Jung Kweon; Khaled Chatila; Na Li; George Taffet; Nikolaos G Frangogiannis
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

7.  Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction.

Authors:  V L Serebruany; P A Gurbel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-01       Impact factor: 8.311

Review 8.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

Review 9.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

Review 10.  Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction.

Authors:  Lei Gao; Xin Hu; Yu-Qi Liu; Qiao Xue; Quan-Zhou Feng
Journal:  Clin Interv Aging       Date:  2014-07-31       Impact factor: 4.458

View more
  35 in total

1.  Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition.

Authors:  Merry L Lindsey; Andriy Yabluchanskiy; Yonggang Ma
Journal:  Cardiology       Date:  2015-08-01       Impact factor: 1.869

Review 2.  Macrophage Plasticity and Function in the Eye and Heart.

Authors:  Zelun Wang; Andrew L Koenig; Kory J Lavine; Rajendra S Apte
Journal:  Trends Immunol       Date:  2019-08-15       Impact factor: 16.687

3.  Attenuated recovery of contractile function in aging hearts following global ischemia/reperfusion: Role of extracellular HSP27 and TLR4.

Authors:  Lihua Ao; Yufeng Zhai; Chunhua Jin; Joseph C Cleveland; David A Fullerton; Xianzhong Meng
Journal:  Mol Med       Date:  2016-12-19       Impact factor: 6.354

Review 4.  Advanced Age Alters Monocyte and Macrophage Responses.

Authors:  Joslyn M Albright; Robert C Dunn; Jill A Shults; Devin M Boe; Majid Afshar; Elizabeth J Kovacs
Journal:  Antioxid Redox Signal       Date:  2016-08-03       Impact factor: 8.401

5.  Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Nicolle L Patterson; Manishabrata Bhowmick; Elizabeth R Flynn; Majdouline Asher; Presley L Cannon; Kristine Y Deleon-Pennell; Gregg B Fields; Merry L Lindsey
Journal:  J Mol Cell Cardiol       Date:  2016-10-13       Impact factor: 5.000

Review 6.  Proteomic analysis of the cardiac extracellular matrix: clinical research applications.

Authors:  Merry L Lindsey; Mira Jung; Michael E Hall; Kristine Y DeLeon-Pennell
Journal:  Expert Rev Proteomics       Date:  2018-01-09       Impact factor: 3.940

7.  Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis.

Authors:  Hiroe Toba; Presley L Cannon; Andriy Yabluchanskiy; Rugmani Padmanabhan Iyer; Jeanine D'Armiento; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

Review 8.  Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling.

Authors:  Merry L Lindsey
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

Review 9.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

Review 10.  The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction.

Authors:  Samantha D Francis Stuart; Nicole M De Jesus; Merry L Lindsey; Crystal M Ripplinger
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.